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Context: Secondary hypogonadism is common in aging men; its natural history and predisposing
factors are unclear.
Objectives: The objectiveswere 1) to identify factors that predispose eugonadalmen (T 10.5 nmol/L) to
developbiochemicalsecondaryhypogonadism(T10.5nmol/L;LH9.4U/L)andsecondaryhypogonadal
men to recover to eugonadism; and 2) to characterize clinical features associatedwith these transitions.
Design: The study was designed as a prospective observational general population cohort survey.
Setting: The setting was clinical research centers.
Participants: The participants were 3369 community-dwelling men aged 40–79 years in eight
European centers.
Intervention: Interventions included observational follow-up of 4.3 years.
Main Outcome Measure: Subjects were categorized according to change/no change in biochemical
gonadal status during follow-up as follows: persistent eugonadal (n 1909), incident secondary hypogo-
nadal(n140),persistentsecondaryhypogonadal(n123),andrecoveredfromsecondaryhypogonadism
to eugonadism (n 96). Baseline predictors and changes in clinical features associatedwith incident sec-
ondary hypogonadismand recovery from secondary hypogonadismwere analyzedby regressionmodels.
Results: The incidence of secondary hypogonadism was 155.9/10 000/year, whereas 42.9% of men with
secondary hypogonadism recovered to eugonadism. Incident secondary hypogonadismwas predicted by
obesity(bodymassindex30kg/m2;oddsratio[OR]2.86[95%confidenceinterval,1.67;4.90];P .0001),
weightgain(OR1.79[1.15;2.80];P .011),andincreasedwaistcircumference(OR1.73[1.07;2.81],P
.026; and OR 2.64 [1.66; 4.21], P .0001, for waist circumference 94–102 and102 cm, respectively).
Incident secondary hypogonadal men experienced new/worsening sexual symptoms (low libido, erectile
dysfunction, and infrequent spontaneous erections). Recovery from secondary hypogonadism was pre-
dictedbynonobesity (OR2.28 [1.21;4.31];P .011),weight loss (OR2.24 [1.04;4.85];P .042),normal
waist circumference(OR1.93 [1.01;3.70];P .048), youngerage(60y;OR2.32 [1.12;4.82];P .024),
andhigher education (OR2.11 [1.05; 4.26];P .037), but symptomsdidnot showsignificant concurrent
improvement.
Conclusion: Obesity-related metabolic and lifestyle factors predispose older men to the develop-
ment of secondary hypogonadism, which is frequently reversible with weight loss. (J Clin Endo-
crinol Metab 100: 3172–3182, 2015)
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Abbreviations: BDI, Beck Depression Index; BMI, body mass index; CI, confidence interval; DSST,
digit symbol substitution test; EUG, eugonadism; HDL, high-density lipoprotein; HG, hypogonad-
ism; HOMA-IR, homeostasis model assessment of insulin resistance; isHG, incident sHG; MetS,
metabolic syndrome; OR, odds ratio; PASE, Physical Activity Scale for the Elderly; pEUG, persistent
EUG; PPT, physical performance test; psHG, persistent sHG; rsHG, recovery from sHG; SF-36, 36-
item Short-Form Health Survey; sHG, secondary HG; WC, waist circumference.
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After the third decade, T decreases in men by 0.4–2%per year (1). Besides aging, other risk factors, par-
ticularly obesity, contribute substantially to the T decline
irrespective of age (1, 2). There is also evidence suggesting
that low T can promote fat accumulation (3) and suggest-
ing a bidirectional relationship between obesity and low T.
Longitudinal data from the European Male Ageing Study
(EMAS) showed that weight gain was progressively asso-
ciated with a decline in T levels without a concomitant
change in LH (4), compatible with secondary hypogonad-
ism (sHG). Furthermore, weight loss was proportionately
associated with increases in T (4), suggesting that sHG is
potentially reversible.
sHG accounts for more than 50% of men with low T in
the general population (5) and in patients with sexual dys-
function (6). To better understand the natural history and
clinical significance of sHG, it is important to further in-
vestigate longitudinally the role of obesity, relative to
other potential risk factors, in predicting the development
of and recovery from sHG.
Symptoms of androgen deficiency in the presence of
low T provide the diagnostic cornerstone of the syndrome
of hypogonadism (7). Late-onset hypogonadism has been
stringently defined by us as subnormal T associated with
three sexual symptoms (5, 8). However, the cross-sec-
tional association between low T and symptoms was at-
tenuated after adjusting for body mass index (BMI) and
comorbidities (5), underlining the multicausal origin of
putative symptoms of hypogonadism in aging men. More-
over, obesity, independent of T, is associated with sexual
(9) and psychological symptoms (10) as well as impaired
physical activity (11). Confirming the appearance of these
symptoms with the development of biochemical hypogo-
nadism and/or their resolution after recovery to eugonad-
ism (EUG) would support their relevance as specific clin-
ical markers of androgen deficiency, important in the
diagnostic workup of men with low T.
The aim of the study was to identify predictors of, and
symptoms associated with, incident sHG (isHG) and re-
covery from sHG (rsHG) in middle-aged and older men
from the general population.
Subjects and Methods
Participants and study design
The EMAS design and methods have been previously described
(12, 13). Briefly, an age-stratified sample of 3369 men aged 40–79
(mean SD, 60 11) years was recruited from population registers
ineightEuropeancenters:Manchester(UnitedKingdom),Leuven(Bel-
gium), Malmö (Sweden), Tartu (Estonia), Lodz (Poland), Szeged
(Hungary), Florence (Italy) and Santiago de Compostela (Spain). Par-
ticipantsattendedresearchclinicsatbaselineand4.3years later(range,
3.0–5.7y) for follow-upassessments (12,13).During thisperiod,193
mendied,334werelosttofollow-up,and106wereinstitutionalizedor
becametoofrail.Ethicalapprovalforthestudywasobtainedaccording
to institutional requirements in each center. All participants provided
written, informed consent. They completed questionnaires at both
baselineand follow-up (12,13)about smoking,alcohol consumption,
and currently treated comorbidities (1). Anthropometric measure-
ments, Reuben’s physical performance test (PPT), and psychomotor
processing speed (digit symbol substitution test [DSST]) were per-
formed according to standardized methods (12, 13). Physical, sexual,
and psychological symptoms were determined from responses to the
Medical Outcomes Study (MOS) 36-item Short-Form health survey
(SF-36), the EMAS Sexual Function Questionnaire, and the Beck De-
pression Inventory (BDI), respectively.
Hormone measurements
Single, fasting morning (before 10 AM) venous blood samples
were obtained at baseline and follow-up. T was measured by
liquid chromatography–tandem mass spectrometry, with paired
baseline and follow-up samples analyzed simultaneously. LH,
FSH, and SHBG were measured by the E170 platform electro-
chemiluminescence immunoassay (Roche Diagnostics). Free T
was calculated using the Vermeulen formula (14). Intra- and
interassay coefficients of variation (CVs) were: T, 4.0 and 5.6%;
SHBG, 1.7 and 3.2%; LH, 1.9 and 3.0%; and FSH, 1.8 and
5.3%, respectively. The lower limit of total T measurement was
0.17 nmol/L (0.05 ng/mL). Insulin was assayed using chemilu-
minescence (coefficients of variation, 3.9 and 5%). Biochemistry
and hematology parameters were performed with standardized
measurements, undertaken in hospital laboratories in each cen-
ter. Insulin resistance was calculated using the homeostasis
model assessment of insulin resistance (HOMA-IR  fasting
insulin [U/mL]  fasting glucose [mmol/L]/22.5) (15).
Gonadal status
ParticipantswithT10.5nmol/LweredefinedasEUG;whenT
10.5 nmol/L and LH9.4 U/L, they were defined as having sHG (5).
Subjectswerefurthercategorizedbytheirchangeingonadalstatusinto:
Sexual Medicine and Andrology Unit (G.R., G.F., M.M.), Department of Experimental Clinical and Biomedical Sciences, University of Florence, 50139 Florence, Italy; Andrology Research
Unit (E.L.C., T.A., J.D.F., F.C.W.W.), Centre for Endocrinology and Diabetes, Institute of Human Development, The University of Manchester, Manchester M13 9WL, United Kingdom;
Department of Andrology and Endocrinology (L.A., D.V.), Katholieke Universiteit Leuven, B 3000 Leuven, Belgium; Arthritis Research UK Centre for Epidemiology (T.W.O.), Institute of
Inflammation and Repair, Faculty of Medical and Human Sciences, Manchester Academic Health Science Centre, University of Manchester and National Institute for Health Research
Manchester Musculoskeletal Biomedical Research Unit, Central Manchester National Health Service Foundation Trust, Manchester M13 9WL, United Kingdom; Department of Obstetrics,
Gynaecology, and Andrology (G.B.), Albert Szent-György Medical University, H6725 Szeged, Hungary; Department of Medicine (F.F.C.), Santiago de Compostela University, Complejo
Hospitalario Universitario de Santiago, Centro de Investigación Biomedical en Red de Fisiopatología Obesidad y Nutricion (CB06/03), Instituto Salud Carlos III, 15076 Santiago de
Compostela, Spain; Department of Clinical Biochemistry (B.K.), Istituto Nazionale Biostrutture e Biosistemi (M.M.), Consorzio Interuniversitario, 00136 Rome, Italy; University Hospital of
South Manchester, Manchester M13 9WL, United Kingdom; Reproductive Medicine Centre (A.G.), Malmö University Hospital, University of Lund, SE-205 02 Malmö, Sweden; Department
of Endocrinology (T.S.H.), Ashford and St Peter’s National Health Service Trust, Surrey KT16 0PZ, United Kingdom; Department of Surgery and Cancer (I.T.H.), Institute of Reproductive
and Developmental Biology, Imperial College London, London W12 0NN, United Kingdom; Department of Andrology and Reproductive Endocrinology (K.K.), Medical University of Łódz´,
90-419 Łódz´, Poland; Department of Human Nutrition (M.E.J.L.), University of Glasgow, Glasgow G12 8QQ, United Kingdom; School of Community-Based Medicine (N.P.), The University
of Manchester, Hope Hospital, Salford M6 8HD, United Kingdom; and Andrology Unit (M.P.), United Laboratories of Tartu University Clinics, 50406 Tartu, Estonia
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1) persistent EUG (pEUG)—EUG at baseline and follow-up; 2) inci-
dent sHG (isHG)—EUG at baseline and sHG at follow-up; 3) persis-
tent sHG (psHG)—sHG at baseline and follow-up; and 4) rsHG—
sHG at baseline and EUG at follow-up.
Statistical analysis
Baseline differences between isHG and pEUG and between
rsHG and psHG in hormone levels, anthropometrics, biochem-
istry, symptoms, and health and lifestyle measures were initially
evaluated by Student’s t test for continuous variables and 2 test
for categorical variables.
Multiple regression models, adjusted for center as a random effect,
were used to account for the hierarchical study design (individuals
nested within center). The relationships between gonadal status and
putative predictors were assessed using multilevel binary logistic re-
gression models, where gonadal status was the outcome, with the
pEUG or psHG group being the referent for the analyses of predictors
of isHG or rsHG, respectively. Nine factors were included as fixed-
effectpredictors:age, smokingstatus (current smoker,yes/no),alcohol
intake (alcoholconsumptionfor5d/wkvs less), education level (low
[compulsoryeducationonly],medium[noncompulsoryeducationbe-
low university level], or high [university education]), Physical Activity
Scale for the Elderly (PASE) score (78 vs78), chronic widespread
pain(yes/no),maritalstatus(nopartner,havingapartnerbutnotliving
together, or having a partner and living together), comorbidity (pres-
ence/absence of at least one self-reported disorder), BMI (25, 25–
29.9, and 30 kg/m2), and waist circumference (WC) (94, 94–
101.9, and102 cm).
The relationship between gonadal status and clinical features
of hypogonadism was investigated using binary logistic regres-
sion models with symptoms dichotomized as stable or new/wors-
ened as the outcome when assessing outcomes of isHG, and as
stable or resolved/improved when assessing outcomes of rsHG.
A symptom was defined as “new” when absent at baseline and
present at follow-up and as “worsened” when present at baseline
but with a lower severity grading than at follow-up. A symptom
was defined as “resolved” when present at baseline and absent at
follow-up and as “improved” when present at follow-up with a
lower severity grading than at baseline.
Differences in clinical characteristics between isHG and
pEUG or between rsHG and psHG at baseline and changes over
time were investigated by multiple logistic regression models
adjusted for age (as a continuous variable), center, baseline BMI
(as a continuous variable), presence of at least one comorbidity
at baseline, smoking, and alcohol intake.
Linear regression models were used to evaluate the associa-
tion between isHG or rsHG and baseline levels or percentage
change of metabolic and hematological parameters, expressed as
continuous variables.
For isHG predictor analysis, weight gain was defined as5%
increase of the baseline value. In the rsHG predictor analysis,
weight loss was defined as 5% decrease of the baseline value.
Results from logistic regression models are presented as odds
ratios (ORs) and 95% confidence intervals (CIs), and results
from linear regression models are presented as coefficients with
95% CIs. All statistical analyses were conducted using SPSS for
Windows 20.1 (IBM).
Results
Natural history of sHG
Of the 3369 men that participated in the EMAS (Figure
1), 193 were excluded at baseline because of medical con-
Figure 1. Study flowchart showing exclusion of subjects and distribution of study sample by gonadal status.
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ditions (known pituitary-testicular diseases and medica-
tions affecting T); 165 died during the follow-up period;
93 were institutionalized or too frail to attend for follow-
up; and 314 were lost to follow-up for other reasons. An-
other 162 were excluded at follow-up because of medical
conditions/medications, and 121 were excluded due to
missing total T and/or LH levels at baseline and/or follow-
up. Among the baseline attendees, the prevalence of sHG
was 10.0% (n  318). In this sHG group, mortality and
lost-to-follow-up rates were 8.2 and 11.3%, compared to
the entire cohort’s rates of 5.2 and 9.9%, respectively. In
the analytical sample of 2268 men, 1909 were pEUG, 140
isHG, 123 psHG, and 96 rsHG (Figure 1). The prevalence
of sHG at follow-up was 11.0%, and the incidence of sHG
from EUG was 6.28% in 4.3 years, or 155.9 per 10 000
per year, or 1.6% per annum. The recovery rate from sHG
to EUG was 30.2% (96 of 318) or 42.9% (96 of 224,
excluding 94 subjects not attending the second assess-
ment) in 4.3 years.
Compared with the analytical sample, men who died,
who were institutionalized, or who were too frail to attend
were older; had lower free T and higher SHBG and gonad-
otropins, but not significantly different total T levels; and
reported more diabetes mellitus and cardiovascular diseases
and worse physical performance (Supplemental Table 1).
Conversely, subjects who were lost to follow-up for other
reasons were similar to the analytical group, except for a
higher prevalence of smoking and metabolic syndrome
(MetS) and lower psychomotor processing speed.
Characteristics of isHG
Lower mean total T, free T, SHBG, LH, and FSH levels
were already apparent in isHG men compared to pEUG men
atbaseline; thesedifferenceswere replicatedandamplifiedat
follow-up (Table 1). isHG men were overweight/obese at
baseline, with higher prevalence of comorbidities and MetS;
these factors increased further at follow-up. isHG men also
showed differences in baseline and follow-up metabolic pro-
Table 1. Characteristics of the Sample at Baseline and Follow-Up Categorized Into Four Groups by Gonadal Status:
pEUG (n  1909), isHG (n  140), psHG (n  123), rsHG Subjects (n  96)
Baseline Follow-Up
pEUG isHG P pEUG isHG P
Age, y 58.3  10.5 57.2  10.4 .251
Total T, nmol/L 18.4  5.4 12.7  2.0 .000 18.1  5.4**** 8.8  1.7**** .000
Calculated free T, pmol/L 322.3  80.2 272.2  48.1 .000 369.3  180.9**** 227.3  117.6**** .000
SHBG, nmol/L 44.5  18.2 29.8  10.4 .000 47.0  19.5**** 28.9  11.5 .000
LH, U/L 5.8  3.2 4.7  2.0 .000 6.1  3.9**** 4.4  1.8* .000
FSH, U/La 5.9 [2.0–24.6] 5.0 [2.0–17.2] .005 5.9 [2.0–26.6]**** 5.0 [1.7–17.6] .000
Hemoglobin, g/L 150.4  10.4 149.6  9.8 .342 150.1  11.4 146.7  12.4* .003
Total cholesterol, mmol/L 5.6  1.0 5.7  1.1 .116 5.3  1.0**** 5.1  1.1**** .073
HDL-cholesterol, mmol/La 1.4 [0.9–2.3] 1.3 [0.8–2.2] .000 1.3 [0.8–2.3]**** 1.2 [0.7–2.5]** .000
Triglycerides, mmol/La 1.2 [0.5–3.8] 1.5 [0.5–5.3] .000 1.2 [0.5–3.7] 1.5 [0.5–6.5] .000
LDL-cholesterol, mmol/L 3.5  0.9 3.6  0.9 .163 3.3  1.0**** 3.1  1.1**** .035
Glucose, mmol/La 5.3 [4.3–8.6] 5.4 [4.3–7.7] .039 5.2 [4.1–8.9]* 5.6 [3.9–9.3] .002
HOMA-IRa 2.0 [0.6-10.0] 2.7 [0.9-18.6] .000 1.5 [0.0–7.1]**** 2.3 [0.6-16.8] .000
MetS, % 18.3 36.0 .000 22.1** 52.7** .000
Weight, kg 82.5  13.1 87.9  13.8 .000 82.4  13.4* 90.7  16.6**** .000
BMI, kg/m2 27.1  3.8 29.2  3.8 .000 27.2  3.9*** 30.2  4.7**** .000
WC, cm 96.7  10.4 102.1  9.5 .000 98.0  11.0**** 105.3  12.7**** .000
PASE score 207.3  87.7 200.1  88.0 .371 183.1  93.5**** 167.1  96.4** .060
1 comorbidity, % 37.8 48.6 .012 52.9**** 70.8**** .000
Frequent alcohol use, % 24.9 20.7 .263 35.4**** 36.6**** .790
Current smoker, % 20.6 17.3 .352 18.2**** 10.8 .032
SF-36 physical function 51.1  7.5 51.9  7.7 .283 50.6  8.2*** 49.3  9.2**** .144
SF-36 mental function 52.0  8.7 53.0  7.9 .208 52.0  9.1 52.1  8.6 .930
BDI 6.3  5.9 6.5  5.8 .633 6.2  6.2 6.4  6.6 .679
PPT rating 24.3  2.4 24.5  2.5 .323 23.8  2.5**** 23.4  2.6**** .054
DSST 28.9  8.4 29.1  8.7 .765 28.02  8.9**** 27.2  9.9**** .374
Abbreviation: LDL, low-density lipoprotein. P values refer to comparisons between pEUG and isHG subjects or between psHG and rsHG subjects,
evaluated by unpaired t test for continuous variable and 2 test for categorical variables. Asterisks refer to comparison between baseline and
follow-up in the same group (pEUG, isHG, psHG or rsHG), evaluated by paired t test for continuous variables and McNemar’s test for categorical
variables. *, P  .05; **, P  .01; ***, P  .001; ****, P  .0001. Continuous variables were expressed as mean  SD, when normally
distributed or median [95% CI], when non-normally distributed. Categorical variables were expressed as percentages. Data reported in bold
highlight significant differences.
a Paired and unpaired t tests have been performed using natural log-transformed data for normalizing skewed distributed variables.
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files, with lower high-density lipoprotein (HDL) and higher
triglycerides, glucose, and HOMA-IR.
Multiple logistic regression modeling identified obesity
(OR  2.86 [1.67; 4.90]; P  .0001) as an independent
predictor of isHG (Figure 2A). Substituting WC for BMI
categories showed that increased WC was a predictor of
isHG (OR 1.73 [1.07; 2.81], P .026; and OR 2.64
[1.66; 4.21], P .0001, for WC of 94–102 cm and WC
102 cm, respectively) and that older men (70 y of age)
demonstrated a significantly lower predisposition to de-
velop sHG compared to younger subjects (OR  0.51
[0.28; 0.96]; P .035) (Figure 2C). Weight gain of5%
was also a risk factor for isHG (OR  1.79 [1.15; 2.80];
P  .011). No significant interaction effect was found
between the variables in the model.
The prevalence of symptoms at baseline and follow-up
and new/worsening symptoms during follow-up are
shown in Table 2. Men with isHG, compared with pEUG,
did not show any difference in the prevalence of symptoms
at baseline before or after adjustment (Table 3 and Figure
3A). isHG was associated with a higher prevalence of de-
creased libido at follow-up, and although just missing sta-
tistical significance, the prevalence of erectile dysfunction
and infrequent morning erections was higher than pEUG
at follow-up (Table 3 and Figure 3B). isHG, however, was
significantly associated with the development or worsen-
ing of all three sexual symptoms and one physical symp-
tom (impaired vigorous activity) (Table 3). Incremental
adjustments for potential confounders (Table 3) showed
that isHG maintained its association only with new/wors-
ening sexual symptoms (Figure 3C).
Compared with pEUG, isHG subjects had significantly
higher total cholesterol at baseline (Table 4). In addition,
isHG was associated with a significant increase in HDL-
cholesterol (Table 4). The apparent relationship between
isHG with increased HDL-cholesterol became insignifi-
cant ( 0.44 [0.08; 0.95];P .096) after adjusting for
those starting lipid-lowering medications during follow-
up. isHG men did not differ from pEUG men at baseline,
but they showed a significant decrease in the perception of
physical well-being (SF-36 physical component score) and
deterioration in PPT rating (Table 4).
Table 1. (Continued)
Baseline Follow-Up
psHG rsHG P psHG rsHG P
Age, y 57.6  10.6 55.8  8.6 .165
Total T, nmol/L 8.3  1.8 9.2  1.0 .000 8.0  2.0 13.3  2.9**** .000
Calculated free T, pmol/L 198.0  49.5 202.4  37.5 .455 240.7  156.2*** 329.7  161.6**** .000
SHBG, nmol/L 22.7  8.9 26.1  7.7 .004 24.5  9.2**** 31.9  10.0**** .000
LH, U/L 3.9  1.8 4.2  1.8 .253 4.1  1.8 4.8  1.6*** .001
FSH, U/La 5.1 [1.7–16.2] 5.2 [1.9–12.9] .914 5.1 [1.5–16.7] 5.3 [1.9–15.7]**** .513
Hemoglobin, g/L 149.5  9.8 150.5  9.1 .431 148.5  12.2 149.4  10.1 .594
Total cholesterol, mmol/L 5.7  1.2 5.5  1.0 .278 5.1  1.3**** 5.2  1.0* .345
HDL-cholesterol, mmol/La 1.2 [0.7–2.2] 1.2 [0.7–2.1] .266 1.1 [0.6–2.1] 1.2 [0.8–1.9] .062
Triglycerides, mmol/La 2.0 [0.8–8.5] 1.5 [0.6–5.8] .009 1.6 [0.7–5.1]* 1.5 [0.6–5.8] .130
LDL-cholesterol, mmol/L 3.4  1.1 3.4  0.9 .607 3.1  1.2** 3.3  1.0 .213
Glucose, mmol/La 5.8 [4.3–9.5] 5.6 [4.1–13.3] .713 5.7 [4.2–9.4] 5.3 [3.8–9.9]* .063
HOMA-IRa 3.7 [1.1–24.4] 3.1 [0.7–21.8] .128 2.3 [0.6–12.5]**** 1.7 [0.5–8.4]**** .003
MetS, % 62.0 37.9 .000 56.5* 44.0 .087
Weight, kg 95.1  16.2 90.8  12.8 .037 95.0  17.6 89.6  13.4* .015
BMI, kg/m2 31.2  4.5 29.5  3.4 .002 31.5  4.8 29.5  3.7 .001
WC, cm 107.3  10.8 103.4  9.6 .006 109.0  11.6*** 104.4  10.1* .004
PASE score 197.5  82.0 221.3  96.6 .058 185.2  91.8* 190.2  110.5* .729
1 comorbidity, % 55.3 46.9 .217 71.7**** 66.7 .436
Frequent alcohol use, % 24.6 17.7 .220 35.8** 26.5 .171
Current smoker, % 18.3 20.8 .654 13.6 19.6 .241
SF-36 physical function 50.5  7.8 50.3  6.9 .799 48.3  8.0** 51.0  8.9 .025
SF-36 mental function 53.1  9.2 52.5  7.2 .580 53.4  8.8 51.7  9.3 .188
BDI 6.6  6.2 5.9  4.7 .332 6.4  6.8 6.4  5.5 .964
PPT rating 24.4  2.4 24.8  2.2 .188 23.7  2.3**** 24.0  2.4**** .340
DSST 29.4  8.1 29.9  8.4 .644 28.5  8.0 28.9  8.7 .777
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Characteristics of rsHG
At baseline, rsHG subjects had higher SHBG and
total T levels as compared with psHG (Table 1). rsHG
men had a more favorable baseline metabolic profile,
with lower triglycerides and a lower prevalence of MetS
than psHG men. They also showed lower weight, BMI,
and WC. rsHG was independently predicted by being
younger and having nonobese BMI (OR  2.32 [1.12;
4.82], P .024; and OR 2.28 [1.21; 4.31], P .011,
respectively) (Figure 2B). Normal WC was a significant
predictor for rsHG (OR  1.93 [1.01; 3.70]; P  .048)
(Figure 2D). A higher level of education predicted rsHG
(OR 2.11 [1.05; 4.26]; P .037) (Figure 2, B and D).
Weight reduction (5%) during follow-up, when sub-
stituted for BMI, was also a predictor for rsHG (OR 
2.24 [1.04; 4.85]; P  .042). No interaction effect was
found between the variables in the model.
Prevalences of symptoms at baseline and follow-up as
well as recovery/improvement of symptoms during fol-
low-up in psHG and rsHG are shown in Table 2. No sig-
nificant association was found between rsHG with either
baseline or follow-up prevalence or recovery/improve-
Figure 2. A, Predictors of isHG. Data are derived from multiple binary regression models, using center as a random-effect covariate and age
(categorized into 10-y age bands), smoking status (current smoker, yes/no), alcohol intake (alcohol consumption  five per week vs less),
education level (low [compulsory education only], medium [noncompulsory education below university level], or high [university education]), PASE
score (78 and 78), chronic widespread pain (yes/no), marital status (no partner, having a partner not living together, or having a partner and
living together), comorbidity (presence/absence of at least one self-reported disorder), and BMI (25, 25–29.9, and 30 kg/m2) as fixed-effect
predictors. Gonadal status was the outcome, with the persistent eugonadal group being the referent category. The ORs are shown on a log scale.
B, Predictors of rsHG. Data are derived from multiple binary regression models, using center as a random-effect covariate and age (dichotomized
into age  60 and age  60 y), smoking status (current smokers, yes/no), alcohol intake (alcohol consumption  five per week vs less), education
level (low and medium [completed noncompulsory education but lower than university level] vs high [university education]), PASE score (78 and
78), chronic widespread pain (yes/no), marital status (no partner vs having a partner), BMI (30 and 30 kg/m2), and comorbidity (presence/
absence of at least one self-reported disorder) as fixed-effect predictors. Gonadal status was the outcome, with the persistent sHG group being
the referent category. The ORs are shown on a log scale. C, Predictors of isHG. Data are derived from multiple binary regression models, using
center as a random-effect covariate and age (categorized into 10-y age bands), smoking status (current smoker, yes/no), alcohol intake (alcohol
consumption  5 per week vs less), education level (low [compulsory education only], medium [noncompulsory education below university level],
or high [university education]), PASE score (78 and 78), chronic widespread pain (yes/no), marital status (no partner, having a partner not living
together, or having a partner and living together), comorbidity (presence/absence of at least one self-reported disorder), and WC (94, 94–102,
and 102 cm) as fixed-effect predictors. Gonadal status was the outcome, with the persistent eugonadal group being the referent category. The
ORs are shown on a log scale. D, Predictors of rsHG. Data are derived from multiple binary regression models, using center as a random-
effect covariate and age (dichotomized into age  60 and age  60 y), smoking status (current smoker, yes/no), alcohol intake (alcohol
consumption  five per week vs less), education level (low and medium [completed noncompulsory education but lower than university
level] vs high [university education]), PASE score (78 and 78), chronic widespread pain (yes/no), marital status (no partner vs having a
partner), WC (102 and  102 cm), and comorbidity (presence/absence of at least one self-reported disorder) as fixed-effect predictors.
Gonadal status was the outcome, with the persistent sHG group being the referent category. The ORs are shown on a log scale. *, P  .05;
***, P  .0001.
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ment of sexual, physical, or psychological symptoms (Fig-
ure 3, D–F). rsHG, compared with psHG, had signifi-
cantly lower total cholesterol and triglycerides at baseline
and a significant decrease in insulin during follow-up (Ta-
ble 4), whereas no significant difference was found for
physical and psychological function.
Discussion
The longitudinal data in this observational cohort of older
men from the general population highlight the role of obe-
sity and weight gain as the most important predictors for
developing sHG, showing for the first time that isHG is
associated with appearance or worsening of sexual symp-
toms only. Another new finding is that sHG is potentially
reversible in a substantial proportion of men and that re-
covery is predicted by nonobesity, weight loss, younger
age, and higher education.
Predictors of isHG
As previously shown by cross-sectional data from
EMAS, BMI is an important correlate of sHG (5). In this
longitudinal evaluation, we are able to confirm that higher
Table 2. Symptoms of the Subjects at Baseline and Follow-Up and Data on Incidence/Worsening and
Recovery/Improvement
Symptoms
Baseline Follow-Up Incidence/Worsening Baseline Follow-Up
Recovery/
Improvement
pEUG isHG P pEUG isHG P pEUG isHG P psHG rsHG P psHG rsHG P psHG rsHG P
Low libido, % 22.7 24.4 .640 26.2** 34.4* .042 17.7 25.6 .029 22.0 16.0 .266 34.2 29.2* .448 7.8 6.8 .786
Erectile dysfunction, % 24.8 25.4 .884 30.7**** 36.4* .172 17.3 28.1 .004 25.2 20.4 .413 37.9** 28.4 .155 2.8 7.2 .146
Reduced morning erections, % 48.5 48.5 .993 51.3** 58.5 .112 17.7 28.1 .011 53.8 55.3 .831 60.0 60.4 .984 8.8 11.1 .577
Reduced vigorous activity, % 19.2 15.1 .236 23.5**** 27.3** .329 13.4 21.4 .017 20.7 21.1 .944 25.2 18.0 .214 7.0 9.0 .605
Impairment in walking 1 km, % 4.0 5.1 .550 7.4**** 10.6* .183 5.2 6.5 .547 7.5 3.2 .174 10.2 6.6 .361 1.8 3.4 .459
Impairment in bending, % 4.2 5.1 .641 5.0 6.8 .347 3.7 4.9 .524 5.0 6.3 .666 7.5 3.3 .198 2.6 4.5 .449
Downheartedness, % 3.7 1.5 .176 3.8 3.0 .650 3.4 2.3 .529 5.8 2.1 .184 2.5 3.4 .717 5.1 1.1 .119
Loss of energy, % 3.7 2.9 .621 5.4** 8.1* .173 4.0 6.0 .264 3.3 1.1 .278 5.9 5.4 .889 1.7 1.1 .713
Fatigue, % 3.7 5.0 .421 4.3 8.1 .037 3.2 5.3 .186 4.9 5.3 .908 5.0 2.2 .285 3.4 5.4 .468
P values refer to comparisons between pEUG and isHG subjects or between psHG and rsHG subjects, evaluated by 2 test. Asterisks refer to
comparison between baseline and follow-up in the same group (pEUG, isHG, psHG or rsHG), evaluated by McNemar’s test. *, P  .05; **, P 
.01; ***, P  .001; ****, P  .0001. Categorical variables were expressed as percentages. Data reported in bold highlight significant differences.
Table 3. Prevalence of Symptoms at Baseline, at Follow-Up, and Change During Follow-Up (Incident or Worsened)
of HG-Related Symptoms
Unadjusted Model 1 Model 2 Model 3 Model 4
Baseline symptoms
Low libido 1.10 [0.73; 1.66]; P  .640 1.22 [0.78; 1.89]; P  .390 1.23 [0.79; 1.93]; P  .362 1.22 [0.78; 1.91]; P  .386 1.47 [0.85; 2.54]; P  .171
Erectile dysfunction 1.03 [0.69; 1.54]; P  .884 1.14 [0.73; 1.80]; P  .564 1.08 [0.68; 1.71]; P  .746 1.02 [0.65; 1.63]; P  .919 0.96 [0.56; 1.65]; P  .891
Reduced morning erections 1.00 [0.71; 1.42]; P  .993 1.07 [0.74; 1.55]; P  .725 1.00 [0.69; 1.46]; P  .976 0.98 [0.67; 1.42]; P  .908 1.07 [0.70; 1.64]; P  .747
Impairment in vigorous activity 0.75 [0.47; 1.21]; P  .237 0.77 [0.47; 1.27]; P  .312 0.65 [0.39; 1.08]; P  .093 0.61 [0.36; 1.02]; P  .058 0.57 [0.31; 1.05]; P  .071
Impairment in walking 1 km 1.27 [0.58; 2.82]; P  .551 1.38 [0.62; 3.11]; P  .432 1.02 [0.43; 2.45]; P  .963 0.95 [0.39; 2.30]; P  .912 1.06 [0.40; 2.83]; P  .903
Impairment in bending 1.21 [0.55; 2.67]; P  .642 1.27 [0.57; 2.83]; P  .557 1.07 [0.47; 2.40]; P  .875 1.05 [0.47; 2.36]; P  .913 1.26 [0.52; 3.06]; P  .611
Downheartedness 0.39 [0.10; 1.61]; P  .192 0.40 [0.10; 1.63]; P  .199 0.38 [0.10; 1.56]; P  .178 0.35 [0.09; 1.47]; P  .153 0.24 [0.03; 1.73]; P  .156
Loss of energy 0.77 [0.28; 2.15]; P  .622 0.79 [0.28; 2.21]; P  .657 0.64 [0.23; 1.80]; P  .394 0.58 [0.21; 1.66]; P  .311 0.39 [0.09; 1.65]; P  .387
Fatigue 1.39 [0.62; 3.07]; P  .423 1.42 [0.64; 3.15]; P  .394 1.28 [0.56; 2.82]; P  .579 1.16 [0.52; 2.63]; P  .717 0.93 [0.32; 2.66]; P  .889
Follow-up symptoms
Low libido 1.47 [1.01; 2.15]; P  .043 1.79 [1.18; 2.72]; P  .007 1.75 [1.14; 2.69]; P  .010 1.73 [1.13; 2.65]; P  .012 2.22 [1.38; 3.57]; P  .001
Erectile dysfunction 1.30 [0.89; 1.88]; P  .173 1.51[0.98; 2.32]; P  .060 1.33[0.86; 2.05]; P  .200 1.28[0.82; 1.98]; P  .277 1.48[0.91; 2.40]; P  .117
Reduced morning erections 1.34 [0.93; 1.92]; P  .113 1.48 [1.01; 2.18]; P  .044 1.34 [0.91; 1.98]; P  .140 1.32 [0.89; 1.95]; P  .164 1.40 [0.90; 2.26]; P  .138
Impairment in vigorous activity 1.22 [0.82; 1.81]; P  .330 1.36 [0.89; 2.09]; P  .156 1.16 [0.75; 1.80]; P  .506 1.10 [0.71; 1.71]; P  .673 1.02 [0.61; 1.70]; P  .949
Impairment in walking 1 km 1.48 [0.83; 2.65]; P  .186 1.73 [0.93; 3.22]; P  .081 1.35 [0.71; 2.57]; P  .362 1.27 [0.66; 2.43]; P  .473 1.17 [0.54; 2.54]; P  .697
Impairment in bending 1.40 [0.69; 2.85]; P  .349 1.53 [0.74; 3.16]; P  .251 1.11 [0.51; 2.41]; P  .797 1.05 [0.48; 2.30]; P  .899 1.07 [0.44; 2.62]; P  .884
Downheartedness 0.79 [0.28; 2.20]; P  .651 0.81 [0.29; 2.26]; P  .685 0.57 [0.17; 1.84]; P  .343 0.53 [0.16; 1.73]; P  .295 0.51 [0.12; 2.14]; P  .505
Loss of energy 1.57 [0.82; 3.00]; P  .176 1.64 [0.85; 3.15]; P  .139 1.37 [0.71; 2.67]; P  .353 1.30 [0.67; 2.54]; P  .439 1.10 [0.48; 2.52]; P  .819
Fatigue 1.98 [1.03; 3.83]; P  .041 2.05 [1.06; .97]; P  .034 1.81 [0.92; 3.55]; P  .084 1.70 [0.86; 3.34]; P  .126 1.66 [0.76; 3.67]; P  .207
Incident/worsening symptoms
Low libido 1.60 [1.05; 2.46]; P  .030 1.79 [1.13; 2.83]; P  .013 1.77 [1.11; 2.82]; P  .017 1.74 [1.09; 2.78]; P  .021 2.16 [1.29; 3.62]; P  .003
Erectile dysfunction 1.86 [1.21; 2.86]; P  .005 2.09 [1.31; 3.32]; P  .002 1.91 [1.19; 3.06]; P  .007 1.87 [1.16; 3.00]; P  .010 2.12 [1.27; 3.56]; P  .004
Reduced morning erections 1.82 [1.14; 2.91]; P  .012 1.98 [1.21; 3.23]; P  .006 1.90 [1.15; 3.13]; P  .012 1.88 [1.14; 3.09]; P  .014 1.79 [1.02; 3.16]; P  .044
Impairment in vigorous activity 1.77 [1.10; 2.85]; P  .019 1.91 [1.16; 3.16]; P  .011 1.75 [1.06; 1.09]; P  .030 1.66 [1.00; 2.75]; P  .050 1.42 [0.78; 2.60]; P  .255
Impairment in walking 1 km 1.26 [0.60; 2.65]; P  .548 1.43 [0.66; 3.12]; P  .368 1.23 [0.56; 2.68]; P  .610 1.46 [0.52; 2.52]; P  .735 1.12 [0.45; 2.83]; P  .806
Impairment in bending 1.32 [0.56; 3.11]; P  .526 1.44 [0.60; 3.46]; P  .410 0.98 [0.38; 2.56]; P  .973 0.91 [0.35; 2.38]; P  .848 0.80 [0.24; 2.71]; P  .721
Downheartedness 0.69 [0.21; 2.22]; P  .531 0.70 [0.22; 2.28]; P  .557 0.68 [0.21; 2.21]; P  .518 0.65 [0.20; 2.11]; P  .468 0.62 [0.15; 2.64]; P  .521
Loss of energy 1.53 [0.72; 3.25]; P  .268 1.57 [0.74; 3.34]; P  .241 1.36 [0.63; 2.92]; P  .429 1.32 [0.61; 2.84]; P  .478 1.09 [0.42; 2.81]; P  .867
Fatigue 1.71 [0.77; 3.83]; P  .191 1.76 [0.78; 3.95]; P  .172 1.62 [0.72; 3.68]; P  .247 1.54 [0.68; 3.52]; P  .302 1.49 [0.57; 3.91]; P  .418
Data are expressed as OR [95% CI] of logistic regression analysis comparing incident sHG with EUG men (referent). Model 1 is adjusted for age
and center; model 2 is adjusted for age, center, and BMI; model 3 is adjusted for age, center, BMI, and presence of comorbidities; and model 4 is
adjusted for age, center, BMI, presence of comorbidities, and drinking and smoking habits. Data reported in bold highlight significant differences.
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BMI and WC predict isHG. Our finding of obesity as a
determinant for T decline, independent of LH, confirms
earlier longitudinal results (16, 17). The association be-
tween obesity and hypogonadism is complex and poorly
understood. Obesity can induce peripheral and central in-
sulin resistance (18), proinflammatory cytokine produc-
tion (TNF and IL-6) from adipocytes (19), and central
nervous system endocannabinoid release (20) that can in-
duce down-regulation of hypothalamic function. In addi-
tion, adipocytokines such as leptin and adiponectin have
Figure 3. Upper panels, Association between incidence of sHG and baseline prevalence (A) or follow-up prevalence (B) or incident/worsening (C)
of hypogonadism-related symptoms (adjusted for age, center, BMI, comorbidities, smoking habits, and alcohol intake), using the group of
persistent eugonadal subjects as referent category. The ORs are shown on a log scale. Lower panels, Association between recovery from sHG and
baseline (D) or follow-up (E) prevalence or recovery/improvement (F) of hypogonadism-related symptoms (adjusted for age, center, BMI,
comorbidities, smoking habits, and alcohol intake), using the group of persistent sHG subjects as referent category. The ORs are shown on a log
scale. *, P  .05; **, P  .01
Table 4. Association between isHG or rsHG and Baseline or Percentage Change From Baseline of Hematological
and Metabolic Parameters and Test Scores Evaluating Physical or Psychological Health
isHG rsHG
Baseline % Change From Baseline Baseline % Change From Baseline
 Coefficient [95%CI] P  Coefficient [95%CI] P  Coefficient [95%CI] P  Coefficient [95%CI] P
Hematological and metabolic parameters
Hemoglobin, g/L 1.99 [4.1; 0.09] .060 1.30 [2.78; 0.17] .083 1.95 [0.86; 4.76] .173 0.17 [1.71; 2.04] .861
Total cholesterol, mmol/L 0.21 [0.01; 0.41] .040 2.39 [5.77; 0.99] .166 0.33 [0.64; 0.02] .038 4.37 [0.70; 9.44] .090
HDL-cholesterol, mmol/La 0.01 [0.05; 0.04] .689 0.50 [0.01; 0.98] .044 0.01 [0.09; 0.07] .729 0.22 [0.74; 0.29] .388
Triglycerides, mmol/La 0.06 [0.05; 0.16] .275 0.22 [0.17; 0.60] .267 0.18 [0.35; 0.01] .041 0.29 [0.44; 1.01] .433
LDL-cholesterol, mmol/L 0.16 [0.02; 0.34] .084 3.06 [8.58; 2.46] .277 0.19 [0.49; 0.11] .210 5.30 [3.64; 14.23] .243
Glucose, mmol/La 0.01 [0.02; 0.04] .485 0.30 [0.02; 0.63] .066 0.03 [0.04; 0.10] .350 0.06 [0.59; 0.46] .814
Insulin, mU/La 0.09 [0.02; 0.19] .114 0.20 [0.31; 0.70] .442 0.05 [0.12; 0.23] .545 1.16 [2.20; 0.13] .029
HOMA-IRa 0.10 [0.02; 0.21] .114 0.12 [0.63; 0.39] .654 0.08 [0.12; 0.29] .412 0.88 [2.02; 0.26] .125
Tests scores for physical or psychological health
SF-36 physical function 1.19 [0.21; 2.58] .095 3.61 [6.85; 0.365] .029 0.64 [2.94; 1.66] .581 4.40 [0.69; 9.49] .089
SF-36 mental function 1.44 [0.28; 3.16] .102 6.81 [32.94; 19.32] .609 1.09 [1.45; 3.64] .397 7.50 [15.40; 0.48] .085
BDI 0.01 [1.17; 1.16] .994 11.55 [17.11; 40.21] .429 1.16 [2.91; 0.59] .191 47.06 [0.10; 93.52] .100
PPT rating 0.24 [0.21; 0.70] .298 2.65 [4.57; 0.74] .007 0.29 [0.37; 0.95] .384 1.12 [3.87; 1.63] .423
DSST 0.53 [0.92; 1.98] .477 3.43 [7.35; 0.49] .086 0.04 [2.36; 2.29] .976 0.65 [8.94; 7.64] .877
Abbreviation: LDL, low-density lipoprotein. Data are adjusted for age, center, BMI, presence of comorbidities, drinking, and smoking habits. The
group of eugonadal subjects at baseline was used as the referent category for the group of isHG, whereas the group with psHG was used as the
referent category for the group that recovers from sHG. Data reported in bold highlight significant differences.
a Paired and unpaired t tests have been performed using natural log-transformed data for normalizing skewed distributed variables.
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been shown to modulate GnRH and gonadotropin secre-
tion (21) and to influence testicular T production (22).
Conversely, the suggested role for an excess of estrogens,
due to an increased aromatase activity in obese subjects, in
reducing the GnRH-gonadotropin secretion has not been
confirmed in obese diabetic (23) and nondiabetic men (5),
their estradiol levels being lower, rather than higher, and
correlated with T levels but not with BMI.
Our results also demonstrated a lower probability that
older men will develop sHG. Cross-sectional data from
EMAS have shown that aging is associated with elevated
gonadotropins and primary hypogonadism (1, 5). Disor-
ders causing a derangement of hypothalamic-pituitary
axis superimposed on a background of high gonadotropin
(as in older men) are less likely to suppress LH to values
below the threshold used to define sHG. Men who at-
tended both phases of the study are healthier as compared
with those who did not (Supplemental Table 1). It is there-
fore conceivable that among those attending for follow-
up, a survival bias may have selected healthier older men
who are less prone to develop sHG (24).
Developing sHG: clinical features
In this study, development of sHG was associated, in-
dependently of BMI, comorbidities, and lifestyle, with
new or worsening sexual symptoms but not physical or
psychological ones. This is consistent with our previous
cross-sectional analyses (8) indicating that these three sex-
ual symptoms are the most specific subjective features as-
sociatedwith lowT. Inaddition, to confirmthe substantial
baseline prevalence (22.7–48.5%) of sexual symptoms,
occurrence of new or worsening symptoms in the pEUG
men is not negligible (almost 18%), albeit at a lower rate
than in isHG men (25.6–28.1%), thus accounting for the
weaker association between isHG and increased preva-
lence of sexual symptoms at follow-up. This emphasizes
the importance of the co-occurrence of all three sexual
symptoms for increasing the probability of a robust syn-
dromic clustering with low T (8), which serves to provide
the operational definition of symptomatic hypogonadism
or late-onset hypogonadism. The longitudinal results,
showinga specific associationbetween thedevelopmentof
sHG with the appearance or worsening of all three sexual
symptoms prospectively, strongly endorse this approach.
In the cross-sectional analyses, physical or psycholog-
ical symptoms did not cluster together with low T, but one
of the physical symptoms, decreased vigor, did show an
inverse correlation with T levels (8). Interestingly, in the
longitudinal study, decreased vigorous activity is the only
nonsexual symptom whose new occurrence or worsening
was significantly associated with isHG, until smoking and
alcohol habits were included as covariates. This empha-
sizes the nonspecific nature of nonsexual symptoms in
sHG. However, when considering the objective evaluation
of physical performance (PPT rating), a significantly
greater reduction was found in isHG men, although this
was not translated into a subjective perception of
deterioration.
Predictors of rsHG
The present results show that sHG is frequently revers-
ible (42.9% when excluding or 30.2% when not excluding
the subjects not attending the second assessment). Rever-
sion to EUG was predicted by lower BMI and WC, weight
loss, younger age, and higher education. The weight as-
sociations are compatible with recent evidence from a gen-
eral population showing that weight loss is associated with
a proportionate increase in T levels (4, 25). Thus, a5%
weight loss was associated with a significant increase of T
levels with the maximum effect in those men who lost
15% of weight when LH as well T increased contem-
poraneously (4). Supervised dieting/exercise or bariatric
surgery in obese men has been shown to increase T and LH
levels proportionally to the amount of weight loss (26).
Interestingly, T increase attained in treated subjects was
higher in younger individuals (26). We found, in addition
to lower weight, that younger age was an independent
predictor of rsHG, suggesting that the potential for weight
loss to improve hypothalamic-pituitary function may be
eroded by adverse effects of aging. A novel finding is that
a higher level of education was an independent predictor
of rsHG. Education is a socioeconomic status surrogate
and an important determinant of health inequality.
Higher education is a protective factor for cardiovascular
diseases and all-cause mortality (27, 28). Changes in be-
havior in response to health education are most beneficial
in higher socioeconomic groups (27–29), which may
translate into improved metabolic status and avoidance of
obesity. Taken together, these results strongly suggest that
sHG or functional hypothalamic suppression associated
with obesity is potentially reversible with weight loss and
amenable to lifestyle-influenced metabolic modifications
especially in younger educated men. Weight loss, espe-
cially in older men, can be unintentional and due to co-
morbidities, cancer cachexia, or other wasting diseases.
However, excluding men with incident cancer or heart
diseases in our analyses did not influence the relationships
between BMI or weight loss with rsHG (data not shown),
suggesting that the observed weight loss in those obese
middle-aged men (mean age, 56 y) with rsHG may well
have been intentional and that the concomitant rise in T is
part of the overall, positive health outcome.
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Recovering from sHG: clinical features
In this study, the anticipated association between rsHG
and resolution/improvement of symptoms was not found.
There are a number of possible explanations. The rela-
tively small sample size may not provide sufficient statis-
tical power to detect small differences between psHG (n
123) and rsHG (n 96), with a minority (two to 11 men)
only showing symptomatic improvements. Both groups
are subjected to uncontrolled multiple and multidirec-
tional influences during follow-up in this noninterven-
tional observational study. The increase in T documented
at one time point at follow-up may not represent a suffi-
ciently sustained improvement to transmute into subjec-
tive symptomatic recovery. Randomized controlled trials
of T replacement therapy demonstrating improvements in
sexual function (30), physical strength (31), and depres-
sive symptoms (32) usually show a 2-fold increase of T
levels into the mid-normal physiological range during
treatment, for a minimum of 24 weeks. The spontaneous
rise in T levels observed in our rsHG subjects is relatively
small by comparison (9.2 nmol/L at baseline, increasing to
13.3 nmol/L at follow-up or a 45% increment) and may
not be sufficient to drive improvements or resolution of
sexual symptoms. Given the high prevalence of sexual
symptoms irrespective of the concentration of circulating
T, a further explanation could be that important nonhor-
monal (eg, psychosocial and relational) factors contribute
to the persistence of symptoms, even after restoration of
normal T levels.
Strengths and limitations
The strengths of this study include a large unbiased
sample from the general population, the prospective de-
sign providing noninterventional longitudinal data to in-
vestigate the natural history and predictors of hypogo-
nadism, and the standardized instruments applied across
centers and between the phases of the study. T levels were
measured by liquid chromatography–tandem mass spec-
trometry, with paired baseline and follow-up samples an-
alyzed simultaneously. Limitations in EMAS have been
described previously (13). The study interval of 4.3 years
may be relatively short for capturing the more subtle
changes in signs and symptoms of hypogonadism in an
observational study. A single LH measurement only was
available to categorize hypogonadism, but its collinearity
with FSH would have minimized any potential misclassi-
fication. Also for T, a single measurement only was avail-
able at each time point. However, T is a stable analyte (33),
and single measurements of T on morning samples can
provide representative and reliable data in large epidemi-
ological studies such as the EMAS.
Conclusions
Our longitudinal data showed that obesity or weight
gain predisposed older men to develop sHG. Older men
were at lower risk. Development of sHG was associated
with the appearance of new or worsening sexual, but not
physical and psychological, symptoms. sHG frequently
remits; this is predicted by lower BMI, lower WC, or
weight loss, as well as younger age and higher education.
Biochemical reversal of sHG to EUG, however, was not
accompanied by a significant symptomatic improvement.
Further studies are indicated to corroborate and extend
the present results.
Acknowledgments
The authors thank the patients who participated in the study; the
research/nursing staff in the eight centers: C. Pott (Manchester),
E. Wouters (Leuven), M. Nilsson (Malmö), M. del Mar Fernan-
dez (Santiago de Compostela), M. Jedrzejowska (Łódz´), H.-M.
Tabo (Tartu), and A. Heredi (Szeged) for their data collection;
and C. Moseley (Manchester) for data entry and project
coordination.
Address all correspondence and requests for reprints to:
Giulia Rastrelli, MD, PhD, Department of Experimental Clini-
cal and Biomedical Sciences, University of Florence, Viale
Pieraccini, 6, 50139 Florence, Italy. E-mail: giulia.rastrelli@
gmail.com.
The European Male Aging Study is funded by the Commis-
sion of the European Communities Fifth Framework Program
“Quality of Life and Management of Living Resources” Grant
QLK6-CT-2001-00258 and facilitated by the Manchester Bio-
medical Research Center and the National Institute for Health
Research Greater Manchester Clinical Research Network. Ad-
ditional support was provided by Arthritis Research UK, the
National Institute for Health Research, and the Manchester Bio-
medical Research Center. The Principal Investigator of EMAS is
Professor Frederick Wu, MD, Andrology Research Unit, Uni-
versity of Manchester, Manchester, United Kingdom.
Disclosure Summary: G.R., E.L.C., T.A., J.D.F., L.A.,
T.W.O., G.B., F.F.C., G.F., B.K., M.M., A.G., T.S.H., K.K.,
M.E.J.L., N.P., M.P., and D.V. have nothing to declare. I.T.H.
has research contracts with Ferring Pharmaceuticals and Pan-
tarhei Bioscience. I.T.H. consults for Novartis. F.C.W.W. has
consulted for Bayer-Schering, Eli Lilly, Repros Therapeutics Inc,
and Besins Healthcare and also participated in advisory board
meetings and lectured on their behalf. F.C.W.W. has received
grant support (2010–2014) from Bayer Schering AG, PAREXEL
International, and Besins Healthcare. D.V. is a senior clinical
investigator supported by the Clinical Research Fund of the Uni-
versity Hospitals Leuven, Belgium.
References
1. Wu FC, Tajar A, Pye SR, et al. Hypothalamic-pituitary-testicular
axis disruptions in older men are differentially linked to age and
doi: 10.1210/jc.2015-1571 press.endocrine.org/journal/jcem 3181
The Endocrine Society. Downloaded from press.endocrine.org by [Andrew Harmon] on 14 January 2016. at 06:31 For personal use only. No other uses without permission. . All rights reserved.The Endocri e Soci ty. Downloaded from p ess.endocri e.org by [${individualUser.displayName}] on 21 June 201 . at 02:52 For personal use only. No other uses without permission. . All ights reserved.
modifiable risk factors: the European Male Aging Study. J Clin En-
docrinol Metab. 2008;93:2737–2745.
2. TravisonTG,AraujoAB,KupelianV,O’Donnell AB,McKinlay JB.
The relative contributions of aging, health, and lifestyle factors to
serum testosterone decline in men. J Clin Endocrinol Metab. 2007;
92:549–555.
3. Saad F, Aversa A, Isidori AM, Gooren LJ. Testosterone as potential
effective therapy in treatment of obesity in men with testosterone
deficiency: a review. Curr Diabetes Rev. 2012;8:131–143.
4. Camacho EM, Huhtaniemi IT, O’Neill TW, et al. Age-associated
changes in hypothalamic-pituitary-testicular function in middle-
aged and older men are modified by weight change and lifestyle
factors: longitudinal results from the European Male Ageing Study.
Eur J Endocrinol. 2013;168:445–455.
5. Tajar A, Forti G, O’Neill TW, et al. Characteristics of secondary,
primary, and compensated hypogonadism in aging men: evidence
from the European Male Ageing Study. J Clin Endocrinol Metab.
2010;95:1810–1818.
6. Corona G, Maseroli E, Rastrelli G, et al. Characteristics of com-
pensated hypogonadism in patients with sexual dysfunction. J Sex
Med. 2014;11:1823–1834.
7. Bhasin S, CunninghamGR, Hayes FJ, et al. Testosterone therapy in
men with androgen deficiency syndromes: an Endocrine Society clin-
ical practice guideline. J Clin Endocrinol Metab. 2010;95:2536–
2559.
8. Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hy-
pogonadism in middle-aged and elderly men. N Engl J Med. 2010;
363:123–135.
9. Han TS, Tajar A, O’Neill TW, et al. Impaired quality of life and
sexual function in overweight and obese men: the European Male
Ageing Study. Eur J Endocrinol. 2011;164:1003–1011.
10. Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and
depression: a systematic review and meta-analysis of longitudinal
studies. Arch Gen Psychiatry. 2010;67:220–229.
11. Riebe D, Blissmer BJ, GreaneyML, Garber CE, Lees FD, Clark PG.
The relationship between obesity, physical activity, and physical
function in older adults. J Aging Health. 2009;21:1159–1178.
12. Lee DM, O’Neill TW, Pye SR, et al. The European Male Ageing
Study (EMAS): design, methods and recruitment. Int J Androl.
2009;32:11–24.
13. Lee DM, Pye SR, Tajar A, et al. Cohort profile: the European Male
Ageing Study. Int J Epidemiol. 2013;42:391–401.
14. Vermeulen A, Stoïca T, Verdonck L. The apparent free testosterone
concentration, an index of androgenicity. J Clin Endocrinol Metab.
1971;33:759–767.
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF,
Turner RC. Homeostasis model assessment: insulin resistance and
-cell function from fasting plasma glucose and insulin concentra-
tions in man. Diabetologia. 1985;28:412–419.
16. Derby CA, Zilber S, Brambilla D,Morales KH,McKinlay JB. Body
mass index, waist circumference and waist to hip ratio and change
in sex steroid hormones: The Massachusetts Male Ageing Study.
Clin Endocrinol (Oxf). 2006;65:125–131.
17. Mohr BA, Bhasin S, Link CL, O’Donnell AB, McKinlay JB. The
effect of changes in adiposity on testosterone levels in older men:
longitudinal results from the Massachusetts Male Aging Study. Eur
J Endocrinol. 2006;155:443–452.
18. Porte D Jr, Baskin DG, Schwartz MW. Insulin signaling in the cen-
tral nervous system: a critical role in metabolic homeostasis and
disease fromC. elegans to humans.Diabetes. 2005;54:1264–1276.
19. Pittas AG, Joseph NA, Greenberg AS. Adipocytokines and insulin
resistance. J Clin Endocrinol Metab. 2004;89:447–452.
20. Pagotto U,MarsicanoG, Cota D, Lutz B, Pasquali R.The emerging
role of the endocannabinoid system in endocrine regulation and
energy balance. Endocr Rev. 2006;27:73–100.
21. George JT, Millar RP, Anderson RA. Hypothesis: kisspeptin medi-
ates male hypogonadism in obesity and type 2 diabetes. Neuroen-
docrinology. 2010;91:302–307.
22. Stokes VJ, Anderson RA, George JT. How does obesity affect fer-
tility in men - and what are the treatment options? Clin Endocrinol
(Oxf). 2015;82(5):633–638.
23. Dhindsa S, Furlanetto R, Vora M, Ghanim H, Chaudhuri A, Dan-
dona P. Low estradiol concentrations in men with subnormal tes-
tosterone concentrations and type 2 diabetes. Diabetes Care. 2011;
34:1854–1859.
24. Lindsted KD, Fraser GE, Steinkohl M, Beeson WL. Healthy volun-
teer effect in a cohort study: temporal resolution in the Adventist
Health Study. J Clin Epidemiol. 1996;49:783–790.
25. Shi Z, Araujo AB, Martin S, O’Loughlin P, Wittert GA. Longitudi-
nal changes in testosterone over five years in community-dwelling
men. J Clin Endocrinol Metab. 2013;98:3289–3297.
26. Corona G, Rastrelli G, Monami M, et al. Body weight loss reverts
obesity-associated hypogonadotropic hypogonadism: a systematic
review and meta-analysis. Eur J Endocrinol. 2013;168:829–843.
27. Mensah GA, Mokdad AH, Ford ES, Greenlund KJ, Croft JB. State
of disparities in cardiovascular health in the United States. Circu-
lation. 2005;111:1233–1241.
28. Hu B, Li W, Wang X, Liu L, Teo K, Yusuf S. Marital status, edu-
cation, and risk of acute myocardial infarction in Mainland China:
the INTER-HEART study. J Epidemiol. 2012;22:123–129.
29. McMichael AJ, McKee M, Shkolnikov V, Valkonen T. Mortality
trends and setbacks: global convergence or divergence? Lancet.
2004;363:1155–1159.
30. CoronaG, Isidori AM, Buvat J, et al.Testosterone supplementation
and sexual function: a meta-analysis study. J Sex Med. 2014;11:
1577–1592.
31. Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on
body composition, bone metabolism and serum lipid profile in mid-
dle-aged men: a meta-analysis. Clin Endocrinol (Oxf). 2005;63:
280–293.
32. Zarrouf FA, Artz S, Griffith J, Sirbu C, Kommor M. Testosterone
and depression: systematic review and meta-analysis. J Psychiatr
Pract. 2009;15:289–305.
33. Vermeulen A, Verdonck G. Representativeness of a single point
plasma testosterone level for the long term hormonal milieu in men.
J Clin Endocrinol Metab. 1992;74:939–942.
3182 Rastrelli et al Secondary Hypogonadism: Development and Recovery J Clin Endocrinol Metab, August 2015, 100(8):3172–3182
The Endocrine Society. Downloaded from press.endocrine.org by [Andrew Harmon] on 14 January 2016. at 06:31 For personal use only. No other uses without permission. . All rights reserved.The Endocri e Soci ty. Downloaded from p ess.endocri e.org by [${individualUser.displayName}] on 21 June 201 . at 02:52 For personal use only. No other uses without permission. . All ights reserved.
